ICOSLG and breast carcinoma: Conversely, a recent work elucidated that a novel ICOSL+ B cell subset in breast cancer tissues emerging after chemotherapy boosted the chemosensitivity by increasing tumor-specific CD8+ T cells and the Th1/Treg ratio, supporting that the effector B cell subtype exerted antitumor immunity to reverse the chemoresistance (9).